Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1881MR)

This product GTTS-WQ1881MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1881MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13303MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ7489MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC-1008
GTTS-WQ8464MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ2605MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ12733MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ9091MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMCgp100
GTTS-WQ4281MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ6000MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 095
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW